VIYASH Viyash Scientific Q2 FY26 results (Jul–Sep 2025) and concall
Viyash delivered a robust Q2 FY26 performance with significant revenue and EBITDA growth, driven by new product launches and operational efficiencies. The NCLT approval for the merger with SeQuent Scientific is a key milestone, with the combined entity poised for sustained high margins and growth. Strategic focus remains on R&D, manufacturing optimization, and expanding into value-added products and companion animal segments.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 709.5%, net profit up 475.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 42 | 338 | 42 | 328 | 340 +710% |
| EBITDA | -2 | 58 | -3 | 49 | 52 +2700% |
| Net profit | 4 | 51 | 4 | 17 | 23 +475% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
